ALK and non-small cell lung carcinoma: The first-generation ALK TKI crizotinib had better progression-free survival (PFS) (10.9 vs. 7.0 months) and a better overall response rate (ORR) (74 vs. 45%) than chemotherapy in treating naïve ALK rearranged {ALK positive [ALK(+)]} NSCLC in the PROFILE 1014 study (2).